Telomerase activity and apoptosis genes as parameters of lymphocyte aging in Down syndrome patients

Egyptian Journal of Medical Human Genetics

Volumn 14, Issue 2, 2013, Pages 171-176

  Abdel Salam, Ekram ^a   Abdel Meguid, Iman ^a   Korraa, Soheir ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY   (Egypt)

Author keywords

Bax; Bcl 2; Down syndrome; ETS 2 gene; Fas; FasL and telomerase

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MESSENGER RNA; PROTEIN BAX; TELOMERASE; TRANSCRIPTION FACTOR ETS 2;

APOPTOSIS; ARTICLE; CELL AGING; CELL DIVISION; CHILD; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN SYNDROME; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD;

EID: 84900368693     PISSN: 11108630     EISSN: 20902441     Source Type: Journal    
DOI: 10.1016/j.ejmhg.2013.01.001     Document Type: Article

References (54)

1. Hassold T., Jacobs P. Trisomy in man. Ann Rev Genet 1984, 18:69-97.
2. Miller R. Neoplasia and Down's syndrome. Ann NY Acad Sci 1970, 171:637-638.
3. Fraumeni J., Manning M., Mitus W. Acute childhood leukemia: epidemiological study by cell type in 1263 cases at the children's cancer research foundation in Boston. J Natl Cancer Inst 1971, 46:461-470.
4. Fabia J., Droletter M. Malformations and leukemia in children with Down syndrome. Pediatrics 1970, 45:60-70.
5. Goldacre M., Wotton C., Seagroatt V., et al. Cancers and immune related diseases associated with Down syndrome: a record linkage study. Arch Dis Child 2004, 89:1014-1017.
6. Yang Q., Rasmussen S., Friedman J. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002, 359:1019-1025.
7. Sanchez-Albisua I., Storm W., Wascher I., Stern M. How frequent is celiac disease in Down syndrome?. Eur J Pediatr 2002, 161:683-689.
8. Karlsson B., Gustafsson J., Hedov G., Ivarsson S.A., Annerén G. Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 1998, 79:242-245.
9. Anwar A., Walker J., Frier B. Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications. Diabet Med 1998, 15:160-163.
10. Garrison M., Jeffries H., Christakis D. Risk of death for children with Down syndrome and sepsis. J Pediatr 2005, 147:748-752.
11. Burgio G., Lanzavecchia A., Maccario R., Plebani A., Ugasio A. Immunodeficiency in Down's syndrome: T lymphocyte subset imbalance in trisomic children. Clin Exp Immunol 1978, 33:298-301.
12. Oster J., Mikkelsen M., Nielsen A. Mortality and life-table in Down's syndrome. Acta Paediatr 1975, 64:322.
13. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729-740.
14. Herbig U., Ferreira M., Condel L., Carey D., Sedivy J. Cellular senescence in aging primates. Science 2006, 311:1257-1268.
15. Wang C., Jurk D., Nelson G., Martin-Ruiz C., von Zglinicki T. DNA damage response and cellular senescence in aging mice. Aging Cell 2009, 8:311-323.
16. Price J., Waters J., Darrah C., Pennington C., Edwards D., Donell S., et al. The role of chondrocyte senescence in osteoarthritis. Aging Cell 2002, 1:57-65.
17. Chang E., Harley C. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995, 92:11190-11194.
18. Harley C., Futcher A.B., Greider C. Telomeres shorten during ageing of human fibroblasts. Int Immunol 1990, 345:458-460.
19. Weng N., Palmer L., Levine B., Lane H., June C., Hodes R. Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunol Rev 1997, 160:43.
20. Valenzuela H., Effros R. Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol 2002, 105:117-125.
21. Akbar A., Vukmanovic-Stejic M. Telomerase in T lymphocytes: use it and lose it?. J Immunol 2007, 178:6689-6694.
22. Nikolaienko O., Nguyen C., Crinc L., Cios K., Gardiner K. Human chromosome 21/Down syndrome gene function and pathway database. Gene 2005, 364:90-98.
23. Hattori M., Fujiyama A., Taylor T., Watanabe H., Yada T., Park H., et al. The DNA sequence of human chromosome 21. Nature 2002, 405:311-319.
24. Baffico M., Perroni L., Rasore-Quartino A., Scartezzini P. Expression of the human ETS-2 oncogene in normal fetal tissues and in the brain of a fetus with trisomy 21. Hum Genet 1989, 83:295-296.
25. Wolvetang E., Bradfield O., Hatzistavrou T., Crack P., Busciglio J., Kola I., et al. Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis. Neurobiol Dis 2003, 14:349-356.
26. Fijiwara S., Fisher R., Seth Bhat N., Showalter S., Zweig M. Characterization and localization of the products of the human homologs of the v-ets oncogene. Oncogene 1988, 2:99-103.
27. Hengartner M. The biochemistry of apoptosis. Nature 2000, 407:770-776.
28. Nagata S. Apoptosis by death factor. Cell 1997, 88:355-365.
29. Hiyama K., Hirai Y., Kyoizumi S., et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995, 155:3711-3715.
30. El Batanouny M., Korraa S., Fekry O. Mitogenic potential inducable by He:Ne laser irradiation on human lymphocytes. J Photochem Photobiol B 2002, 68(1):1-7.
31. Kim N., Piatyszek M., Prowse K., Harley C., West M., Ho P., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266(5193):2011-2015.
32. Kiener P., Davis P., Rankin B., Klebanoff S., Ledbetter J., Starling G., et al. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 1997, 159:1594-1598.
33. Laffon B., Pásaro E., Méndez J. Effects of styrene-7,8-oxide over p53, p21, bcl-2 and bax expression in human lymphocyte cultures. Mutagenesis 2001, 16(2):127-132.
34. Owen-Schaub L., Angelo L., Radinsky R., Ware C., Gesner T., Bartos D. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?. Cancer Lett 1995, 94(1):1-8.
35. El-Ahmady O., El-Salahy E., Mahmoud M., Wahab A., Eissa S., Khalifa A. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up. Am J Physiol Heart Circ Physiol 2003, 284:H1560-H1569.
36. Ioannou Y., Chen F. Quantification of DNA fragmentation in apoptosis. Nucleic Acid Res 1996, 24(5):883-992.
37. Jenkins E., Ye L., Velinov M., Krinsky-McHale S., Zigman W., Schupf N., et al. Mild cognitive impairment identified in older individuals with down syndrome by reduced telomere signal numbers and shorter telomeres measured in microns. Am J Med Genet B Neuropsychiatr Genet 2012, 159B(5):598-604.
38. Jenkins E.C., Tassone F., Ye L., Gu H., Xi M., Velinov M., et al. Reduced telomere length in older men with premutation alleles of the fragile X mental retardation 1 gene. Am J Med Genet A 2008, 146A(12):1543-1546.
39. Sukenik-Halevy R., Biron-Shental T., Sharony R., Fejgin M.D., Amiel A. Telomeres in trisomy 21 amniocytes. Cytogenet Genome Res 2011, 135(1):12-18.
40. Helguera P., Pelsman A., Pigino G., Wolvetang E., Head E., Busciglio J. Ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J Neurosci 2005, 25(9):2295-2303.
41. Nakamura E., Tanaka S. Biological ages of adult men and women with Down's syndrome and its changes with ageing. Mech Ageing Dev 1998, 105(1-2):89-103.
42. Epstein C. Specificity versus non-specificity in the pathogenesis of aneuploid phenotypes. Am J Med Genet 1988, 29:161-165.
43. Maroulakou I., Papas T., Green J. Differential expression of ets-1 and ets-2 proto-oncogenes during murine embryogenesis. Oncogene 1994, 9:1551-1565.
44. Bhat N., Thompson C., Lindsten T., June C., Fujiwara S., Koizumi S., et al. Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1. Proc Natl Acad Sci USA 1990, 87(10):3723-3727.
45. Seidl R., Fang-Kircher S., Bidmon B., Cairus N., Luber G. Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brain of adult patients with Down syndrome. Neurosci Lett 1999, 260(1):9-12.
46. Antonucci A., Di Baldassarre A., Di Giacomo F., Styppia I., Palka G. Detection of apoptosis in peripheral blood cells of 31 subjects affected with Down syndrome before and after zinc therapy. Ultrastruct Pathol 1997, 21(5):449-452.
47. Seidl R., Bidmon B., Bajo M., Yoo P.C., Cairns N., LaCasse E.C., et al. Evidence for apoptosis in the fetal Down syndrome brain. J Child Neurol 2001, 16(6):438-442.
48. Bisht D., Gupta S.C., Misra V., Mital V.P., Sharma P. Effect of low intensity laser radiation on healing of open skin wounds in rats. Indian J Med Res 1994, 100:43-46.
49. Zamzami N., Marchetti P., Castedo M., et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995, 182:367-377.
50. Anderson M.K., Hernandez-Hoyos G., Diamond R.A., Rothenberg E. Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. Development 1999, 126:3131-3148.
51. Ghysdael J., Boureux A. Oncogenes as transcriptional regulators 1997, 2988. Basel-Boston-Berlin Birkhauser Verlag. M. Yaniv, J. Ghysdael (Eds.).
52. Rameil P., Lécine P., Ghysdael J., Gouilleux F., Kahn-Perlès B., Imbert J. IL-2 and long-term T cell activation induce physical and functional interaction between STAT5 and ETS transcription factors in human T cells. Oncogene 2000, 19(17):2086-2097.
53. Brunner T., Mogil R., LaFace D., Yoo N., Mahboubi A., Echeverri F., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995, 373:441-444.
54. Effros R., Dagarag M., Spaulding C., Man J. The role of CD8 T cell replicative senescence in human aging. Immunol Rev 2005, 205:147-157.